Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
Apotex Inc. (“Apotex” or the “Company”), the Canadian-based global health company,today announced thatHealth Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization. https://mma.prnewswire.com/media/2723755/Apotex_Inc__Apotex_receives_Health_Canada_approval_for_Aflivu__.jpg This […]